Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 161

The DOI matches its Crossref record.

Prostate carcinoma presentation, diagnosis, and staging: An update from the National Cancer Data Base

Open access
Miller, David C., Hafez, Khaled S., Stewart, Andrew, Montie, James E., Wei, John T. · 2003 · Cancer

Abstract

BACKGROUND: Based on the 1998 Patient Care Evaluation (PCE) from the American College of Surgeons National Cancer Data Base (NCDB), the authors described contemporary nationwide patterns of prostate carcinoma presentation, diagnosis, and staging. METHODS: The authors reviewed 54,212 cases from the 1998 PCE. Demographics, presenting signs and symptoms, tumor characteristics, prostate biopsy techniques, and use of staging modalities were evaluated. RESULTS: The mean age of patients in the sample was 68 years. Among patients with available data, 87.5% had a prostate specific antigen (PSA) level of 4 ng/mL or higher, 83.1% had American Joint Committee on Cancer (AJCC) Stage I–II lesions, 80.2% had well or moderately differentiated cancers, and 68.7% of newly diagnosed patients were asymptomatic. Compared with symptomatic patients, asymptomatic patients were more likely to have localized disease (84.6% vs. 78.2%, P < 0.01) and well or moderately differentiated tumors (82.2% vs. 74.6%, P < 0.01). Transrectal ultrasound‐guided prostate biopsy was the most common method of tissue confirmation (45.4%). Radionuclide bone scintigraphy was the most frequently employed staging modality (48.7%). Use of various staging evaluations was more frequent among patients at increased risk for disseminated disease (PSA > 10 ng/mL and/or high‐grade tumors) versus patients at lower risk (PSA ≤ 10 and low to moderate‐grade tumors) for metastatic disease (P < 0.005). CONCLUSIONS: Most newly diagnosed patients with prostate carcinoma are asymptomatic and have moderately differentiated and organ‐confined disease. Compared with symptomatic patients, tumors in asymptomatic men are associated with lower pretreatment PSA levels, AJCC stage, and tumor grade. Selective use of staging evaluations, based on risk of metastatic disease, may be relatively uncommon. The NCDB remains a unique and rich source of novel patient care information and serves as a national point of reference for prostate carcinoma presentation, diagnosis, and staging. Cancer 2003;98:1169–78. © 2003 American Cancer Society. DOI 10.1002/cncr.11635

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.11635

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 161

Metadata

Authors
Miller, D. C., Hafez, K. S., Stewart, A., Montie, J. E., & Wei, J. T.
Venue
Cancer
Publisher
Wiley
Published
2003-07-31
Volume
98
Issue
6
Pages
1169-1178
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2117792163
Cited by
161
References
0
FWCI
6.00
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prostate carcinoma presentation, diagnosis, and staging: An update from the National Cancer Data Base. https://app.cochat.ai/papers/10.1002/cncr.11635
The paper
Miller, D. C., Hafez, K. S., Stewart, A., Montie, J. E., & Wei, J. T. (2003). Prostate carcinoma presentation, diagnosis, and staging: An update from the National Cancer Data Base. Cancer. https://doi.org/10.1002/cncr.11635

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.